替洛利生

替洛利生
臨床資料
商品名英语Drug nomenclatureWakix, Ozawade
其他名稱Tiprolisant; Ciproxidine; BF2.649
AHFS/Drugs.comMonograph
MedlinePlusa619055
核准狀況
给药途径By mouth
藥物類別英语Drug classHistamine H3 receptor inverse agonists
ATC碼
法律規範狀態
法律規範
识别信息
  • 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine
CAS号362665-56-3  checkY
903576-44-3  checkY[NIH]
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard英语CompTox Chemicals Dashboard (EPA)
化学信息
化学式C17H26ClNO
摩尔质量295.85 g·mol−1
3D模型(JSmol英语JSmol
  • C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl
  • InChI=1S/C17H26ClNO/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19/h7-10H,1-6,11-15H2 checkY
  • Key:NNACHAUCXXVJSP-UHFFFAOYSA-N checkY

替洛利生是一种治疗发作性睡病成人白天嗜睡的药物,[2]它是一种组胺3(H3)受体英语Histamine H3 receptor拮抗剂/反激动剂[2]是同类药物中第一种上市的药物。[3]它可增强大脑中组胺能神经元的活动,从而提高人的清醒度;[4]其副作用包括睡眠困难、恶心、焦虑等。[5]

参考文献

[编辑]
  1. ^ Summary Basis of Decision (SBD) for Wakix. Health Canada. 23 October 2014 [29 May 2022]. (原始内容存档于2022-12-22). 
  2. ^ 2.0 2.1 2.2 Wakix- pitolisant hydrochloride tablet, film coated. DailyMed. 6 November 2019 [18 August 2020]. (原始内容存档于2020-08-11). 
  3. ^ FDA Approves Pitolisant for Daytime Sleepiness in Patients with Narcolepsy. Pharmacy Times. [18 August 2020]. (原始内容存档于2020-08-12). 
  4. ^ Syed YY. Pitolisant: First Global Approval. Drugs. 20 July 2016, 76 (13): 1313–1318. PMID 27438291. S2CID 42684839. doi:10.1007/s40265-016-0620-1. 
  5. ^ Drug Trials Snapshots: Wakix. U.S. Food and Drug Administration (FDA). 14 August 2019 [18 March 2020]. (原始内容存档于2020-12-22).